Protein release profiles and morphology of biodegradable microcapsules containing an oily core

2001 ◽  
Vol 76 (3) ◽  
pp. 313-326 ◽  
Author(s):  
Bi Botti C Youan ◽  
Tanise L Jackson ◽  
Lorenzo Dickens ◽  
Carmen Hernandez ◽  
Godfried Owusu-Ababio
2014 ◽  
Vol 31 (11) ◽  
pp. 2940-2951 ◽  
Author(s):  
Feng Wan ◽  
Morten Jonas Maltesen ◽  
Sune Klint Andersen ◽  
Simon Bjerregaard ◽  
Stefania G. Baldursdottir ◽  
...  

2017 ◽  
Vol 5 (23) ◽  
pp. 4487-4498 ◽  
Author(s):  
D. Dutta ◽  
C. Fauer ◽  
K. Hickey ◽  
M. Salifu ◽  
S. E. Stabenfeldt

Solvent evaporation parameters and ethanol content during PLGA/PLLA microparticle (MP) fabrication affect protein distribution and MP structure, thereby altering the protein release profiles.


1997 ◽  
Vol 12 (1) ◽  
pp. 49-55 ◽  
Author(s):  
Yoshifumi Murata ◽  
Norie Katayana ◽  
Takashi Kajita ◽  
Etsuko Miyamoto ◽  
Susumu Kawashima

1970 ◽  
Vol 48 (12) ◽  
pp. 1472-1479
Author(s):  
Harry C. Lord III

Thermal release profiles and retention coefficients of injected argon ions were investigated as functions of substrate composition and prior ion-irradiation history. Samples of forsterite, enstatite, oligoclase, obsidian, and cold-rolled steel were irradiated with various sequences of 1 keV H+, 4 keV He+, and 40 keV Ar+. The release temperature of the maximum argon concentration was found to be a function of incident Ar+ dose and pre-irradiation history but not substrate composition. The hydrogen or helium pre-irradiation converted the volume diffusion argon release to a low temperature defect diffusion release. An increase in the incident dose of Ar+ ions resulted in increasing the percentage of the argon released by defect diffusion, and also decreased the argon retention coefficient.


Separations ◽  
2021 ◽  
Vol 8 (1) ◽  
pp. 7
Author(s):  
Fadi Aldeek ◽  
Nicholas McCutcheon ◽  
Cameron Smith ◽  
John H. Miller ◽  
Timothy L. Danielson

In recent years, oral tobacco-derived nicotine (OTDN) pouches have emerged as a new oral tobacco product category. They are available in a variety of flavors and do not contain cut or ground tobacco leaf. The on!® nicotine pouches fall within this category of OTDN products and are currently marketed in seven (7) flavors with five (5) different nicotine levels. Evaluation of the nicotine release from these products is valuable for product assessment and product-to-product comparisons. In this work, we characterized the in vitro release profiles of nicotine from the 35 varieties of on!® nicotine pouches using a fit-for-purpose dissolution method, employing the U.S. Pharmacopeia flow-through cell dissolution apparatus 4 (USP-4). The nicotine release profiles were compared using the FDA’s Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. The cumulative release profiles of nicotine show a dose dependent response for all nicotine levels. The on!® nicotine pouches exhibit equivalent percent nicotine release rates for each flavor variant across all nicotine levels. Furthermore, the nicotine release profiles from on!® nicotine pouches were compared to a variety of other commercially available OTDN pouches and traditional pouched smokeless tobacco products. The percent nicotine release rates were found to be dependent on the product characteristics, showing similarities and differences in the nicotine release profiles between the on!® nicotine pouches and other compared products.


Biomolecules ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 635
Author(s):  
Ding Li ◽  
Menglong Wang ◽  
Wen-Liang Song ◽  
Deng-Guang Yu ◽  
Sim Wan Annie Bligh

A side-by-side electrospinning process characterized by a home-made eccentric spinneret was established to produce the Janus beads-on-a-string products. In this study, ketoprofen (KET) and methylene blue (MB) were used as model drugs, which loaded in Janus beads-on-a-string products, in which polyvinylpyrrolidone K90 (PVP K90) and ethyl cellulose (EC) were exploited as the polymer matrices. From SEM images, distinct nanofibers and microparticles in the Janus beads-on-a-string structures could be observed clearly. X-ray diffraction demonstrated that all crystalline drugs loaded in Janus beads-on-a-string products were transferred into the amorphous state. ATR-FTIR revealed that the components of prepared Janus nanostructures were compatibility. In vitro dissolution tests showed that Janus beads-on-a-string products could provide typical double drugs controlled-release profiles, which provided a faster immediate release of MB and a slower sustained release of KET than the electrospun Janus nanofibers. Drug releases from the Janus beads-on-a-string products were controlled through a combination of erosion mechanism (linear MB-PVP sides) and a typical Fickian diffusion mechanism (bead KET-EC sides). This work developed a brand-new approach for the preparation of the Janus beads-on-a-string nanostructures using side-by-side electrospinning, and also provided a fresh idea for double drugs controlled release and the potential combined therapy.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 260
Author(s):  
Mariana Morais ◽  
Patrícia Coimbra ◽  
Maria Eugénia Pina

The visual impairment that often leads to blindness causes a higher morbidity rate. The goal of this work is to create a novel biodegradable polymeric implant obtained from coaxial fibers containing the dispersed drug—acetazolamide—in order to achieve sustained drug release and increase patient compliance, which is of the highest importance. Firstly, during this work, uncoated implants were produced by electrospinning, and rolled in the shape of small cylinders that were composed of uniaxial and coaxial fibers with immobilized drug inside. The fibers were composed by PCL (poly ε-caprolactone) and Lutrol F127 (poly (oxyethylene-b-oxypropylene-b-oxyethylene)). The prepared implants exhibited a fast rate of drug release, which led to the preparation of new implants incorporating the same formulation but with an additional coating film prepared by solvent casting and comprising PCL and Lutrol F127 or PCL and Luwax EVA 3 ((poly (ethylene-co-vinyl acetate)). Implants were characterized and in vitro release profiles of acetazolamide were obtained in phosphate buffered saline (PBS) at 37 °C. The release profile of the acetazolamide from coated implant containing Luwax EVA 3 is considerably slower than what was observed in case of coated implants containing Lutrol F127, allowing a sustained release and an innovation relatively to other ocular drug delivery systems.


Sign in / Sign up

Export Citation Format

Share Document